DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Celiac Disease (CD)- Market Insights, Epidemiology and Market Forecast - 2023 - EU5" drug pipelines to their offering.
The total prevalent cases of Celiac Disease in EU5 is expected to accentuate up to 3.2 Million by 2023 at a Compound Annual Growth Rate (CAGR) of 2.21% from 2013-2023, while the diagnosed prevalent population of Celiac Disease shall grow at a CAGR of 2.86% for the forecast period (2013-2023).
It also includes historical and forecasted epidemiological data for the total prevalent and diagnosed prevalent cases of Celiac Disease in EU5 from 2013-2023.
Celiac disease is a genetic autoimmune disease where the indigestion of gluten leads to damage in the small intestine. The number of ways celiac disease can affect patients, combined with a lack of training in medical schools and primary care residency programs, contributes to the poor diagnosis rate.
Currently it is estimated that 80% of the celiac disease population remains undiagnosed. Prevalence in Western Europe ranges between 1 in 133. It is higher in relatives of people with celiac disease. Women are affected more commonly than men, but there is no age predilection.
There is no targeted therapy approved for celiac disease. The current standard of care treatment involves a gluten free diet (GFD). Steroids and immunosuppressants are used to reduce symptoms in severe cases. Owing to the expected launch of Larazotide Acetate (Innovate Pharmaceuticals) in 2021 followed by the launch of Latiglutenase (ImmunogenX/Abbvie) in 2023, shall lead to a hike in the otherwise stable, market size of celiac disease. The EU5 market size is expected to grow at a CAGR of 49.3% from 2013-2023.
Key Topics Covered:
- Celiac Disease Overview
- Celiac Disease Types
- Non-Responsive or Refractory CD
- Disease Management
- Disease Treatment
- Treatment of Celiac Disease
- Treatment of Non-Responsive or Refractory Celiac Disease (RCD)
- Current Unmet Medical Needs
- Epidemiology Parameters
- Iceberg Model
- Genetic Predisposition
- Epidemiology & Patient Population
- Emerging Phase III Therapies
- Market Drivers
- Market Barriers
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/2w2zdn/celiac_disease